Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

Active:	No
Cancer Type:	Breast Cancer Unknown Primary	NCT ID:	NCT05169567
Trial Phases:	Phase III	Protocol IDs:	18238 (primary) NCI-2022-05155 2021-002301-10 I3Y-MC-JPEF
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Eli Lilly and Company
NCI Full Details:	http://clinicaltrials.gov/show/NCT05169567

Summary

This study will evaluate the effect of adding abemaciclib to fulvestrant for the
treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor
2-negative (HER2-) breast cancer that progressed or recurred after previous treatment
with a type of drug known as a CDK4/6 inhibitor and endocrine therapy. Participation
could last up to 5 years, depending on how you and your tumor respond.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.